571189-16-7

Basic information

• Product Name: 1-BOC-4-(6-NITROPYRIDIN-3-YL)PIPERAZINE
• Synonyms: 1-BOC-4-(6-NITROPYRIDIN-3-YL)PIPERAZINE;tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate;4-(6-Nitro-3-pyridinyl)-1-piperazinecarboxylic acid tert-butyl ester;4-(6-Nitropyridin-3-yl)piperazine-1-carboxylic acid tert-butyl ester;1-Piperazinecarboxylic acid, 4-(6-nitro-3-pyridinyl)-, 1,1-diMethylethyl ester;NaMe:4-(6-Nitro-3-pyridinyl)-1-piperazinecarboxylic acid tert-butyl ester;Tert. butyl-4-(6-Nitropyridin-3-yl)piperazino-1-carboxylate;4-(6-nitropyridin-3-yl)-1-piperazinecarboxylic acid tert-butyl ester
• CAS NO: 571189-16-7
• Molecular Formula: C₁₄H₂₀N₄O₄
• Molecular Weight: 308.336
• EINECS: 1592732-453-0
• Product Categories: Anticancer
• Mol File: 571189-16-7.mol
• Article Data: 64

Chemical Properties

• Boiling Point: 480.1°C at 760 mmHg
• Flash Point: 244.1°C
• Appearance: /
• Density: 1.258
• Vapor Pressure: 2.24E-09mmHg at 25°C
• Refractive Index: 1.562
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 0.11±0.70(Predicted)
• CAS DataBase Reference: 1-BOC-4-(6-NITROPYRIDIN-3-YL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-4-(6-NITROPYRIDIN-3-YL)PIPERAZINE(571189-16-7)
• EPA Substance Registry System: 1-BOC-4-(6-NITROPYRIDIN-3-YL)PIPERAZINE(571189-16-7)

Safety Data

• Hazardous Substances Data: 571189-16-7(Hazardous Substances Data)

Usage

Uses

tert-butyl 4-(6-nitropyridin-3-yl)piperazine-1-carboxylate is used in preparation of Heterocyclic compound as cdk-hdac double-channel inhibitor.

InChI:InChI=1/C14H20N4O4/c1-14(2,3)22-13(19)17-8-6-16(7-9-17)11-4-5-12(15-10-11)18(20)21/h4-5,10H,6-9H2,1-3H3

Upstream product

• 775288-71-6 1-(6-nitropyridin-3-yl)piperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 39856-50-3 5-bromo2-nitropyridine 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 1072-97-5 5-bromo-2-pyridylamine 
• 52092-47-4 5-chloro-2-nitropyridine 
• 779345-37-8 5-fluoro-2-nitro-pyridine 
• 21717-96-4 2-amino-5-fluoropyridine 
• 1221726-34-6 1-(6-nitropyridin-3-yl)piperazine hydrochloride 
• 110-85-0 piperazine 
• 311-28-4 tetra-(n-butyl)ammonium iodide 

Downstream Products

• 1433821-84-1 tert-butyl 4-(6-(6-bromoimidazo[1,2-a]pyrazin-8-ylamino)pyridin-3-yl)piperazine-1-carboxylate 
• 1433821-90-9 6-bromo-N-(5-(piperazin-1-yl)pyridin-2-yl)imidazo[1,2-a]pyrazin-8-amine 
• 1433821-95-4 6-bromo-N-(5-(4-methylpiperazin-1-yl)pyridin-2-yl)imidazo[1,2-a]pyrazin-8-amine 
• 1433822-00-4 4-fluoro-2-(8-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)imidazo-[1,2-a]pyrazin-6-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1433819-96-5 2-(5-fluoro-2-(hydroxymethyl)-3-(8-(5-(4-methylpiperazin-1-yl)pyridin-2-ylamino)imidazo[1,2-a]pyrazin-6-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1433820-14-4 10-[5-fluoro-2-(hydroxymethyl)-3-(8-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-ylamino)imidazo[1,2-b]pyridazin-6-yl)phenyl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0^2,6]dodeca-2⁽⁶⁾,7-dien-9-one 
• 1433820-69-9 2-[3-(hydroxymethyl)-4-[8-[[5-[4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]imidazo[1,2-a]pyridin-6-yl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one 
• 1433821-24-9 tert-butyl 4-(6-(6-chloroimidazo[1,2-a]pyridin-8-ylamino)pyridine-3-yl)piperazine-1-carboxylate 
• 1433821-28-3 6-chloro-N-(5-(piperazin-1-yl)pyridine-2-yl)imidazo[1,2-a]pyridin-8-amine 
• 1433821-33-0 6-chloro-N-(5-(4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)imidazo[1,2-a]pyridin-8-amine 
• 1433819-80-7 2-(5-fluoro-2-(hydroxymethyl)-3-(8-(5-(4-(oxetan-3-yl)piperazine-1-yl)pyridine-2-ylamino)imidazo[1,2-a]pyridin-6-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 866084-31-3 tert?butyl 4?(6?((6?(1?butoxyvinyl)?8?cyclopentyl?5?methyl?7?oxo?7,8?dihydropyrido[2,3?d]pyrimidin?2?yl)amino)pyridin?3?yl)piperazine?1?carboxylate 
• 571190-30-2 PD 0332991 

Relevant articles and documents

Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma

Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play determinant roles in MM, but no remarkable progress has been obtained from clinical trials of CDK4/6 inhibitors for MM. To discover novel CDK6 inhibitors with better potency and high druggability, structure-based virtual screening was conducted to identify compound 10. Further chemical optimization afforded a better derivative, compound 32, which exhibited strong inhibition of CDK4/6 and showed high selectivity over 360+ kinases, including homologous CDKs. The in vivo evaluation demonstrated that compound 32 possessed low toxicity (LD50 > 10,000 mg/kg), favorable bioavailability (F% = 51%), high metabolic stability (t1/2 > 24 h) and strong anti-MM potency. In summary, we discovered a novel CDK4/6 inhibitor bearing favorable drug-like properties and offered a great candidate for MM preclinical studies.

CDK6/DYRK2 Double-target inhibitor as well as preparation method and application thereof

The present invention discloses a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. The invention also discloses a preparation method of the compound and application of the compound in prevention and/or treatment of cancers or tumor-related diseases, especially breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, human glioma and other diseases. The compound provided by the invention is expected to be developed into a new generation of anti-cancer drugs.

Intermediate compound as well as preparation method and application thereof

The invention discloses an intermediate compound as well as a preparation method and application thereof. The synthesized intermediate compound is used for preparing targeted anti-cancer drugs, such as CDK4, CDK6, DYRK2 and other inhibitors, and is used for preventing and/or treating cancers or tumor related diseases including breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer and human glioma. The intermediate compound is simple in preparation condition, high in reaction yield and stable in performance.